[Role of extracellular matrix degradation enzyme for glioma invasion].
Nakada
Mitsutoshi
M
Department of Neurosurgery, Division of Neuroscience, Graduate School of Medical Science, Kanazawa University.
D051722:ADAM Proteins / Q000235:genetics / Q000502:physiology*; D001932:Brain Neoplasms / Q000188:drug therapy / Q000201:enzymology* / Q000473:pathology*; D003606:Dacarbazine / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D015195:Drug Design; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D005109:Extracellular Matrix / Q000378:metabolism*; D005910:Glioma / Q000188:drug therapy / Q000201:enzymology* / Q000473:pathology*; D006801:Humans; D006877:Hydroxamic Acids / Q000494:pharmacology / Q000627:therapeutic use; D061965:Matrix Metalloproteinase Inhibitors; D020782:Matrix Metalloproteinases / Q000502:physiology*; D009361:Neoplasm Invasiveness; D012697:Serine Endopeptidases / Q000502:physiology; D000077204:Temozolomide; D013754:Tetracyclines / Q000494:pharmacology / Q000627:therapeutic use
D004791:Enzyme Inhibitors; D006877:Hydroxamic Acids; D061965:Matrix Metalloproteinase Inhibitors; D013754:Tetracyclines; C117155:tetracycline CMT-3; D003606:Dacarbazine; C100342:marimastat; D012697:Serine Endopeptidases; D051722:ADAM Proteins; D020782:Matrix Metalloproteinases; D000077204:Temozolomide